Selection of individuals for prevention of fractures due to bone fragility

Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 14, Issue 2, 2000, Pages 233-249

  Seeman, Ego ^a,b  

^a Department of Medicine ^*  (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bone loss; Fractures; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

AGING; BODY DENSITY; BONE ATROPHY; BONE MINERAL; BONE REMODELING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; MASS SCREENING; MORBIDITY; MORTALITY; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT SELECTION; POPULATION RISK; REVIEW; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0033762941     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2000.0071     Document Type: Article

References (40)

1. Cooper C, Campion G & Melton LJ. Hip fractures in the elderly: a world-wide projection. Osteoporosis International 1992; 2: 285-289.
2. Cooper C, Atkinson EJ, Jacobsen SJ et al. Population-based study of survival after osteoporotic fracture. American Journal of Epidemiology 1993; 137: 1001-1005.
3. Poore G, Atkinson EJ, O'Fallon WM & Melton LJ III. Determinants of reduced survival after hip fracture in men. Clinical Orthopedics 1995; 319: 260-265.
4. Ray NF, Chan JK, Thamer M & Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the US in 1995: report from the National Osteoporosis Foundation. Journal of Bone and Mineral Research 1997; 12: 24-35.
5. Seeman E. The dilemma of osteoporosis in men. American Journal of Medicine 1995; 98 (supplement IA): 75S-87S.
6. Center JR, Nguyen TV, Schneider D et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 878-882.
7. Kannus P, Parkkari J, Sievanen H, Heinonen A et al. Epidemiology of hip fractures. Bone 1996; 18: 57S-61S.
8. Parfitt AM. Skeletal heterogeneity and the purposes of bone remodelling: implications for the understanding of osteoporosis. In Marcus R, Feldman D & Kelsey J (eds) Osteoporosis, pp 315-329. San Diego: Academic Press, 1995.
9. Aaron JE, Makins NB & Sagreiy K. The microanatomy of trabecular bone loss in normal aging men and women. Clinical Orthopedics and Related Research 1987; 215: 260-271.
10. Weinstein RS & Manolagas SC. Apoptosis and osteoporosis. American Journal of Medicine 2000; 108: 153-164.
11. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial. Lancet 1996; 348: 1535-1541.
12. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. Journal of the American Medical Association 1998; 280: 2077-2082.
13. Pols HAP, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporosis International 1999; 9: 461-468.
14. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. Journal of the American Medical Association 1999; 282: 1344-1352.
15. Ettinger B, Black DM, Knickerbocker RK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomised clinical trial. Journal of the American Medical Association 1999; 282: 637-645.
16. Lindsay R, Hart DM, Forrest C & Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980; 2: 1151-1154.
17. Lufkin EG, Wahner HW, O'Fallon WM et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Annals of Internal Medicine 1992; 117: 1-9.
18. Seeman E. Osteoporosis: trials and tribulations. American Journal of Medicine 1997; 103: 74S-87S.
19. McClung M, Eastell R, Bensen W et al. Risedronate reduces hip fracture risk in elderly women with osteoporosis. World Conference on Osteoporosis [Abst. 559]. Osteoporosis International 2000; (supplement 2).
20. 3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine 1992; 327: 1637-1642.
21. Lips P, Graafmans WC, Ooms ME et al. Vitamin D supplementation and fracture incidence in elderly people. Annals of Internal Medicine 1996; 124: 400-406.
22. Black DM, Blackwell T, Ettinger B et al. Does raloxifene reduce non-vertebral fracture risk in women with very low BMD: results from the MORE study [Abst. 123]. Osteoporosis International 2000; (supplement 2).
23. Melton LJ III, Atkinson EJ, Cooper C et al. Vertebral fractures predict subsequent fractures. Osteoporosis International 1999; 10: 214-221.
24. Black DM, Arden NK, Palermo L et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Journal of Bone and Mineral Research 1999; 14: 821-828.
25. Klotzbuecher CM, Ross PD, Landsman PB et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. Journal of Bone and Mineral Research 2000; 15: 721-739.
26. Cuddihy M-T, Gabriel SE, Crowson CS et al. Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporosis International 1999; 9: 469-475.
27. Lindsay R, Watts N, Roux C et al. Increased risk of new vertebral fracture within 1 year of an incident vertebral fracture. World Conference on Osteoporosis [Abst. 209]. Osteoporosis International 2000; (supplement 2).
28. Delaet CEDH, van der Klift M, Hofman A & Pols HAP. The NOF estimates for fracture risk revisited. World Conference on Osteoporosis [Abst. 205]. Osteoporosis International 2000; (supplement 2).
29. Hopper JL & Seeman E. Bone density in twins discordant for tobacco use. New England Journal of Medicine 1994; 330: 387-392.
30. Garnero P, Hausher E, Chapuy MC et al. Markers of bone resorption predict hip fracture in elderly women: the Epidos prospective study, Journal of Bone and Mineral Research 1996; 11: 1531-1538.
31. Bjarnsson NH, Christiansen C, Duong T & Delmas PD. Pretreatment BMD and vertebral fracture status as well as change in osteocalcin are all predictors for the risk of incident vertebral fracture during raloxifene therapy. World Conference on Osteoporosis [Abst.]. Osteoporosis International 2000; (supplement 2).
32. Chrischilles E, Shireman T & Wallace R. Cost and health effects of osteoporotic fractures. Bone 1994; 15: 377-386.
33. Rose G. The Strategy of Preventive Medicine. Oxford: Oxford University Press, 1992.
34. Storm T, Thamsborg G, Steiniche T et al. Effect of cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New England Journal of Medicine 1990; 322: 1265-1271.
35. Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate therapy of post-menopausal osteoporosis. New England Journal of Medicine 1990; 323: 73-79.
36. Tilyard MW, Spears GFS, Thomson J & Dovey S. Treatment of postmenopausal osteporosis with calcitriol or calcium. New England Journal of Medicine 1992; 326: 357-362.
37. Ott SM & Chesnut C. Calcitriol treatment is not effective in postmenopausal osteoporosis. Annals of Internal Medicine 1991; 84: 267-274.
38. Ebeling PR, Wark JD, Yeung S et al. Effects of calcitriol or calcium on bone mineral density, bone turnover and fractures in men with idiopathic osteoporosis. Australian and New Zealand Bone and Mineral Society Annual Scientific Meeting 1998, 26-28 August.
39. Johnell O, Scheele W, Lu Y & Lakshmanan M. Effects of raloxifene, alendronate and raloxifene and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research 1999; (supplement 14): S157.
40. Hochberg MC, Ross PD, Black D et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteporosis. Arthritis and Rheumatism 1999; 42: 1246-1254.